A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

(Baylor College of Medicine) A phase II clinical trial of neratinib in patients with metastatic breast cancer carrying a HER2 mutation produces encouraging results in that about 30 percent of patients and a promising diagnostic tool for metastatic breast cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news